Ligand Pharmaceuticals Incorporated
LGND · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $1,960 | $1,235 | $1,127 | $2,569 |
| - Cash | $72 | $23 | $45 | $20 |
| + Debt | $7 | $6 | $88 | $324 |
| Enterprise Value | $1,895 | $1,219 | $1,170 | $2,874 |
| Revenue | $167 | $131 | $196 | $242 |
| % Growth | 27.3% | -33.1% | -18.8% | – |
| Gross Profit | $156 | $96 | $143 | $179 |
| % Margin | 93.4% | 73.3% | 73.1% | 74.3% |
| EBITDA | $41 | $101 | $81 | $143 |
| % Margin | 24.4% | 76.8% | 41.4% | 59.1% |
| Net Income | -$4 | $52 | -$33 | $57 |
| % Margin | -2.4% | 39.7% | -17% | 23.7% |
| EPS Diluted | -0.22 | 2.94 | -1.98 | 3.34 |
| % Growth | -107.5% | 248.5% | -159.3% | – |
| Operating Cash Flow | $97 | $50 | $138 | $79 |
| Capital Expenditures | -$20 | -$54 | -$18 | -$9 |
| Free Cash Flow | $77 | -$4 | $120 | $70 |